Similarly, miR-708 and miR-503 can modulate ovarian cancer resistance to cisplatin through regulating the Akt pathway (Qin et al., 2017; Wu et al., 2018).Recently, emerging evidence has shown that miRNAs are aberrantly expressed in ovarian cancer, and some of them regulate different mRNAs and inhibit cisplatin resistance. The gene discussed is AKT1; the disease is ovarian carcinoma.